Sanxing Guo Selected Research

Neoplasms (Cancer)

3/2024	Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‑institution experience.
9/2023	AIFM2 promotes hepatocellular carcinoma metastasis by enhancing mitochondrial biogenesis through activation of SIRT1/PGC-1α signaling.
1/2023	Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.
7/2020	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
10/2014	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sanxing Guo Research Topics

Disease

5	Neoplasms (Cancer) 03/2024 - 10/2014
3	Neoplasm Metastasis (Metastasis) 03/2024 - 01/2022
3	Lung Neoplasms (Lung Cancer) 02/2024 - 01/2022
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2022
2	Adenocarcinoma of Lung 01/2023 - 01/2022
2	Breast Neoplasms (Breast Cancer) 07/2020 - 10/2014
2	Triple Negative Breast Neoplasms 07/2020 - 01/2020
1	Carcinoma (Carcinomatosis) 03/2024
1	Disease Progression 01/2024
1	Hepatocellular Carcinoma (Hepatoma) 09/2023
1	Cancer Pain 04/2023
1	Glioma (Gliomas) 04/2023
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2023
1	Multiple Sclerosis 01/2023
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2023
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Hepatitis 09/2017
1	Pathologic Complete Response 10/2014

Drug/Important Bio-Agent (IBA)

4	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2022
3	taxaneIBA 07/2020 - 10/2014
2	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2023
2	Formaldehyde (Formol)FDA Link 07/2020 - 10/2014
2	ParaffinIBA 07/2020 - 10/2014
2	AnthracyclinesIBA 07/2020 - 10/2014
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2020 - 10/2014
1	AntigensIBA 03/2024
1	tepotinibIBA 01/2024
1	aflutinibIBA 01/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2024
1	NADH oxidaseIBA 09/2023
1	Sirtuin 1IBA 09/2023
1	Dexmedetomidine FDA Link 04/2023
1	Temozolomide (Temodar)FDA LinkGeneric 04/2023
1	Tramadol (K315)FDA LinkGeneric 04/2023
1	Morphine (MS Contin)FDA LinkGeneric 04/2023
1	Analgesics (Analgesic Drugs)IBA 04/2023
1	Flurbiprofen (Froben)FDA LinkGeneric 04/2023
1	Capsules (Microcapsules)IBA 01/2023
1	Glial Fibrillary Acidic ProteinIBA 01/2023
1	GlucosidesIBA 01/2023
1	Connexin 43 (Connexin43)IBA 01/2023
1	Monoclonal AntibodiesIBA 01/2023
1	Proto-Oncogene Proteins B-rafIBA 01/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	Epidermal Growth Factor (EGF)IBA 07/2020
1	ginsenoside Rg1IBA 09/2017
1	Hormones (Hormone)IBA 10/2014
1	human ERBB2 proteinIBA 10/2014

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2024 - 10/2014
4	Therapeutics 02/2024 - 10/2014
2	Neoadjuvant Therapy 07/2020 - 10/2014
1	Immunotherapy 01/2024
1	Adjuvant Chemotherapy 01/2020